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Abstract
Background: In the light of the breast density legislation in the USA, it is important to know a woman’s breast cancer
risk, but particularly her risk of a tumor that is not detected through mammographic screening (interval cancer).
Therefore, we examined the associations of automatically measured volumetric breast density with screen-detected
and interval cancer risk, separately.
Methods: Volumetric breast measures were assessed automatically using Volpara version 1.5.0 (Matakina, New Zealand)
for the first available digital mammography (DM) examination of 52,814 women (age 50 − 75 years) participating in the
Dutch biennial breast cancer screening program between 2003 and 2011. Breast cancer information was obtained
from the screening registration system and through linkage with the Netherlands Cancer Registry. We excluded
all screen-detected breast cancers diagnosed as a result of the first digital screening examination. During a median
follow-up period of 4.2 (IQR 2.0–6.2) years, 523 women were diagnosed with breast cancer of which 299 were screen-
detected and 224 were interval breast cancers. The associations between volumetric breast measures and breast
cancer risk were determined using Cox proportional hazards analyses.
Results: Percentage dense volume was found to be positively associated with both interval and screen-detected breast
cancers (hazard ratio (HR) 8.37 (95% CI 4.34–16.17) and HR 1.39 (95% CI 0.82–2.36), respectively, for Volpara density
grade category (VDG) 4 compared to VDG1 (p for heterogeneity < 0.001)). Dense volume (DV) was also found to
be positively associated with both interval and screen-detected breast cancers (HR 4.92 (95% CI 2.98–8.12) and HR
2.30 (95% CI 1.39–3.80), respectively, for VDG-like category (C)4 compared to C1 (p for heterogeneity = 0.041)). The
association between percentage dense volume categories and interval breast cancer risk (HR 8.37) was not significantly
stronger than the association between absolute dense volume categories and interval breast cancer risk (HR 4.92).
Conclusions: Our results suggest that both absolute dense volume and percentage dense volume are strong markers
of breast cancer risk, but that they are even stronger markers for predicting the occurrence of tumors that are not
detected during mammography breast cancer screening.
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Background
The female breast consists of fibroglandular (dense) and
fat (nondense) tissue. It is known that breast density,
measured as either the percentage or absolute amount
of fibroglandular tissue in the breast, is a strong breast
cancer risk factor [1–3]. Besides this, high breast density
is also known to hinder the detection of tumors during
mammographic screening [4–6]. These findings have led
to legislation in the USA that mandates disclosure of
breast density information to women undergoing mam-
mography screening. Depending on their breast density,
women may opt for supplemental screening, for example
by ultrasound or magnetic resonance imaging (MRI).
When breast density measures are used as a tool to
stratify women for different screening strategies, it is im-
portant that these measures are highly reproducible as it
is undesirable that the likelihood of a woman being clas-
sified as having dense breasts is dependent on which
radiologist she goes to. Another prerequisite is that these
measures can be obtained in the daily practice of high-
throughput screening.
Breast density can be measured using several methods.
The most widely used methods are visual estimation
using Breast Imaging - Reporting and Data System (BI-
RADS) density categories and the semi-automatic area-
based Cumulus method [7]. The former is mostly used
by radiologists in clinical and screening practice. The lat-
ter is mostly used for research purposes. Both methods
have been shown to be related to breast cancer risk.
However, they also have some disadvantages. BI-RADS
density classification has high inter-reader variability and
Cumulus is very time-consuming. Hence, neither
method is optimal for stratification in breast cancer
screening [8–12].
Nowadays, digital mammography (DM) is widely used
and several software packages are available to measure
breast density fully automatically on digital mammo-
grams. Most packages report volumetric breast density
measures, which are user-independent and developed
with the intention to give an accurate and reproducible
estimation of the amount of fibroglandular tissue in the
breast using physics-based modeling based on informa-
tion in the header of the raw digital images [13, 14]. This
is in contrast to the aforementioned methods (BI-RADS
and Cumulus) that measure the projected area of dense
tissue on a mammogram. Density measured with auto-
matic volumetric methods has also been examined in re-
lation to breast cancer risk and results were found to be
comparable to results from studies where BI-RADS or
Cumulus were used to quantify breast density. In gen-
eral, percentage dense volume (PDV) seemed to be a
stronger breast cancer risk predictor than dense volume
(DV) [15–18].Absolute dense volume represents the
amount of fibroglandular tissue in the breast and is
hypothesized to be positively associated with breast
cancer risk as this is considered to be the actual tissue
where breast cancers develop [19, 20]. Percent dense
volume is the proportion of fibroglandular (dense) tissue
in the breast. This has sometimes been suggested to be a
stronger risk factor than absolute dense volume, which
would indicate that the ratio between the two tissues is
important, or that nondense volume, which is part of
the denominator of percent dense volume, is a protective
factor for breast cancer risk. In a large meta-analysis, Pet-
tersson et al. previously studied the associations between
both absolute and percentage dense area and breast can-
cer risk. Their results suggest that percentage dense area
is a stronger risk indicator than absolute dense area, but
some heterogeneity between study results remained [3].
By using automatically assessed volumetric breast density
measures instead of projected area measures we hope to
gain more insight into these ambiguities and to find the
best measure to be used in breast cancer risk prediction.
In light of discussions on the need for supplemental
screening after a negative mammogram, measures that
indicate the risk of a tumor that is not detected at mam-
mography screening (interval cancer) may be even more
relevant. BI-RADS density and other area-based density
measures have been shown to be strongly related to the
risk of interval cancer [4, 21–26]. The relationship be-
tween automatic volumetric density methods and the
risk of screen-detected and interval cancers, respectively,
has not yet been studied. In this study, we used a fully
automatic method to obtain several volumetric density
measures, and assess their relationship with breast can-
cer risk. We distinguished between the risk of tumors
that are detected at mammography (screen-detected
cancers) or in the interval between two screening rounds
(interval cancers), in a large cohort with digital mammo-
grams from the population-based Dutch breast cancer
screening program.
Methods
Study population
The study population consists of 52,814 women aged be-
tween 50 and 75 years who had one or more digital mam-
mographic examinations at the Preventicon screening unit
in Utrecht, the Netherlands, between 2003 and 2011. The
Preventicon screening unit is one screening unit of the
Foundation of Population Screening Mid-West screening
region, which is one of the five screening regions of the
Dutch biennial breast cancer screening program. All re-
gions follow the same screening protocol. The Dutch pro-
gram involves mammography only. By participating in the
Dutch screening program, women consent to their data
being used for evaluation and improvement of the screen-
ing, unless they have indicated otherwise.
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Data collection
In this breast cancer screening cohort, for each partici-
pant we collected the first unprocessed DM examination
that was taken at the Preventicon screening unit be-
tween 2003 and 2011. All mammograms were acquired
using Lorad Selenia DM systems (Hologic, Danbury,
Conn.). If this was the participant’s first screening exam-
ination within the program, this examination included
the two standard views, craniocaudal (CC) and mediolat-
eral oblique (MLO). If this was not her first screening
examination within the program, i.e. when she had
undergone film screen mammography in earlier rounds,
MLO was the routinely acquired view and the CC view
was taken only when indicated (e.g. high breast density,
visible abnormality). A CC view was present in 57% of
the subsequent screening examinations. Information
about follow up was obtained from the screening regis-
tration system. Women were followed until breast can-
cer diagnosis (event), death or until 2 years after the last
available mammogram, whichever came first. Informa-
tion on breast cancer development was obtained from
the screening registration system and through linkage
with the Netherlands Cancer Registry. This also included
information on the mode of detection: through screen-
ing mammography (screen-detected cancer) or through
diagnosis in the 24 months screening interval after a
negative screening mammogram (interval cancer). Inter-
val cancers diagnosed more than 24 months after a
negative screening mammogram were not included for
analysis. Within the screening program, information on
risk factors other than age is not collected.
Volumetric mammographic density assessment
Absolute dense volume (DV), percentage dense volume
(PDV) and absolute nondense volume (NDV) were auto-
matically assessed from unprocessed mammograms of
the left and right breasts, using Volpara density (version
1.5.0, Matakina, Wellington, New Zealand). Although
normally both MLO and CC views would be used for
calculating volumetric density measures with Volpara,
here we used the mean of only the left and right MLO
views for the risk analyses, since this is the routinely ac-
quired view and CC views were not available for all
women. In this way we ensured that breast density was
assessed in the exact same way in all participants. Vol-
para density grades (VDGs) were constructed based on
this average PDV using the standard Volpara cutoff
points from version 1.5.0 (VDG1: 0% ≤ PDV <4.5%,
VDG2: 4.5% ≤ PDV <7.5%, VDG3: 7.5% ≤ PDV <15.5%,
VDG4: PDV ≥15.5%). The VDGs are designed to mimic
the fourth edition of the BI-RADS breast density cat-
egories. We chose to use this edition, because it is most
comparable to what has been used in previous papers.
Statistical analysis
Descriptive statistics of age and breast measures (DV,
PDV, NDV and VDG) were determined. Continuous
breast measures were transformed using the natural
logarithm (ln) to obtain normal distributions. Pearson
correlation coefficients for correlation between different
breast measures and between breast measures and age
were determined. We also assessed the correlation be-
tween breast measures on the MLO and CC views
among women who had both views available, and on the
MLO views of the left and right breasts.
We examined the associations between the different
breast density measures and breast cancer risk by calculat-
ing hazard ratios (HR) and their 95% confidence intervals
(95% CI) using Cox proportional hazards analyses for
quartiles (quartile cutoffs were determined based on
the distribution of the different density measures in the
whole cohort at baseline) and continuous measures
(per standard deviation (SD) increase of the ln-
transformed measure) of DV and PDV. We also de-
termined associations between breast cancer risk and
two additional breast density measures: (1) VDG cat-
egories (Volpara BI-RADS) and (2) a categorized DV
variable in which the cutoff points were created as to
obtain the same group sizes as with the VDG categories
(VDG-like categories).
To minimize the number of breast cancer cases in
the model that were diagnosed based on the same
mammogram as was used for breast density assessment,
we excluded all screen-detected breast cancer cases of
women diagnosed on the basis of their first digital
screening examination.
Cox proportional hazards analyses were used to
examine the association between breast density and
breast cancer risk. Age was used as the underlying
time scale with entry and exit time defined as age at
time of the first available DM and age at breast can-
cer diagnosis, death or censoring 2 years after the last
DM before 1 January 2012. In this way, the con-
founding effect of age was taken into account. Two
models were constructed. The first model only con-
tained one of the density measures. The second
model was adjusted for NDV in case the model in-
cluded quartiles, categories or continuous measures of
DV. We found that DV and NDV volume were posi-
tively correlated (Pearson correlation = 0.50). By
adjusting for NDV we attempted to determine the in-
dependent effect of DV on breast cancer risk, without
the interference of NDV. Models containing a PDV
measure (including VDG) were not adjusted for NDV,
since NDV is already part of PDV (PDV = DV/(DV +
NDV)). The proportional hazards assumption was
evaluated by Schoenfeld residual plots and log-minus-
log plots, and the assumption was not violated. To
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examine the presence of a linear trend in HRs over
the quartiles and categories of breast measures, quar-
tile and category variables were added to the models
as continuous variables.
To examine the association between the different
density measures and screen-detected or interval cancers
and to test whether the association was statistically sig-
nificantly different between density measures and
screen-detected versus interval cancers, the method of
Lunn and McNeil was used for competing risk analysis
[27, 28]. Cox proportional hazards analysis was used for
this method, with time of follow up as the underlying
time scale. Age at time of first available DM was added
as a covariate in the models to take the confounding ef-
fect of age into account.
A bootstrap method was used to determine whether
measures based on PDV or DV were stronger breast
cancer risk factors. This was done for VDG versus VDG-
like categories, quartiles of PDV versus quartiles of DV
and continuous PDV versus continuous DV. The differ-
ences between coefficients for models containing a PDV
or DV measure were determined within 2000 bootstrap
samples. A difference of 0 indicates that there is no dif-
ference between the effect of DV and PDV on breast
cancer risk. A 95% CI that does not include 0 means that
one measure is statistically significantly more strongly
related to breast cancer risk than the other measure.
In addition, a sensitivity analysis was performed where
we only used the contralateral MLO view for breast can-
cer cases and for non-breast cancer cases the MLO view
of a random chosen side, with the same left and right
distribution as that of the breast cancer cases.
For the main analysis both invasive and in situ breast
cancers were used. In a sensitivity analysis, we only took
invasive breast cancers into account for data analysis.
For all breast density measures, we compared the
fourth category or quartile with the first. Nowadays,
often the second category is used as the reference cat-
egory, as BI-RADS breast density category 2 is the most
prevalent category among women of breast cancer
screening age. To be able to compare with other studies,
we also present results using the second category or
quartile of each breast density measure as reference cat-
egory. Statistical analyses were performed using SPSS
version 22 and R version 3.2.0.
Results
After excluding cases of screen-detected breast cancer,
diagnosed on the basis of the first available digital
screening examination, 523 breast cancers, including
299 screen-detected and 224 interval breast cancers
were used for analyses. At the first digital screening
mammogram the median age was 56 years (IQR 51–63)
in women who did not develop breast cancer (N =
52,291), 59 years (IQR 54–64) in women who were diag-
nosed with screen-detected breast cancer and 55 years
(IQR 50–62) in women diagnosed with interval breast
cancer during follow up. The median total number of
screening rounds in which women participated (analog
(if applicable) and digital together) was 5 (IQR 2–8), 7
(IQR 4–9) and 4 (IQR 2–7) in women who were not di-
agnosed with breast cancer, were diagnosed with a
screen-detected breast cancer and were diagnosed with
interval cancer, respectively. The median follow-up time
after the first digital mammogram until breast cancer
diagnosis (event), death or end of follow up, was 4.2 years
(IQR 2.0–6.2), 3.8 years (IQR 2.1–4.3) and 2.3 (IQR 1.3–
4.0), in women with no diagnosis of breast cancer,
screen-detected breast cancer and interval breast cancer,
respectively (Table 1).
PDV was strongly negatively correlated with NDV
(-0.70, p < 0.01)) and positively correlated with DV (0.27,
p < 0.01). DV was positively correlated with NDV (0.50,
p < 0.01). DV and PDV were both negatively correlated
with age (-0.16 and -0.29, respectively, p < 0.01), whereas
NDV was positively correlated with age (0.14, p < 0.01).
There was strong correlation between breast measures
of the left and right breast and between CC and MLO
views. Correlations between the MLO views of the left
and right breast for DV, PDV and NDV was 0.86, 0.91
and 0.98, respectively (N = 52,410 and p < 0.01 for all
three). Correlation between MLO and CC views of the
right breast was 0.86, 0.90 and 0.97 DV, PDV and NDV,
respectively (N = 38,997 and p < 0.01 for all three).
Association between breast density measures and breast
cancer risk (total)
In Fig. 1 and Table 2 it is shown that all breast density
measures (VDG, quartiles of PDV, continuous PDV, VDG-
like categories, quartiles of DV and continuous DV) were
positively associated with breast cancer risk, with HR 3.14
(95% CI 2.17–4.55) for VDG category 4 compared to
category 1 and HR 3.55 (95% CI 2.49–5.05) for VDG-like
category 4 compared to category 1, and HR 2.42 (95% CI
1.83–3.20) for PDV and 2.60 (95% CI 1.96–3.45) for DV
quartile 4 compared to quartile 1. The risk estimates of
PDV and DV measures were not statistically significantly
different from one another (Table 3).
The HRs for continuous measures of PDV and DV
were 1.36 (95% CI 1.25–1.48) and 1.45 (95% CI 1.32–
1.60), respectively, for one standard deviation increase in
the ln-transformed continuous measure (not statistically
significantly different from one another (Table 3)).
Association between breast density measures and screen-
detected breast cancer risk
Figure 2 and Table 4 show the association between dif-
ferent breast density measures and the risk of screen-
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detected breast cancer. The measures based on DV
(VDG-like categories, quartiles of DV and continuous
DV) were positively associated with the risk of screen-
detected breast cancer. The associations between PDV
measures (VDG, quartiles of PDV and continuous PDV)
and screen-detected breast cancer risk were increased,
but were not statistically significant or were borderline
significant.
The HRs were 2.30 (95% CI 1.39–3.80) and 1.39 (95%
CI 0.82–2.36) for VDG-like category and VDG category
4 compared to category 1, respectively and were 2.24
(95% CI 1.51–3.31) and 1.36 (95% CI 0.97–1.94) for the
Table 1 Characteristics of 52,814 women undergoing digital mammography (first time) between 2003 and 2011
No breast cancer
(N = 52,291)
Screen-detected cancer
(N = 299)
Interval cancer
(N = 224)
Age (years)a, median (IQR) 56 (51 ; 63) 59 (54 ; 64) 55 (50 ; 62)
Number of screening rounds participated in, median (IQR) 5 (2 ; 8) 7 (4 ; 9) 4 (2 ; 7)
Follow up (years)b, median (IQR) 4.2 (2.0 ; 6.2) 3.8 (2.1 ; 4.3) 2.3 (1.3 ; 4.0)
VDG categories, n (%)
Category 1 10,458 (20.0) 46 (15.4) 12 (5.4)
Category 2 21,276 (40.7) 143 (47.8) 72 (32.1)
Category 3 15,856 (30.3) 89 (29.8) 100 (44.6)
Category 4 4,701 (9.0) 21 (7.0) 40 (17.9)
Continuous density measures, median (IQR)
Dense volume (cm3)a 57.7 (42.8 ; 78.8) 63.2 (49.0 ; 83.5) 67.7 (48.9 ; 93.2)
Percent dense volume (%)a 6.4 (4.8 ; 9.8) 6.5 (5.0 ; 9.4) 8.5 (6.2 ; 13.6)
Nondense volume (cm3)a 805.0 (518.8 ; 1183.7) 929.1 (585.6 ; 1298.7) 720.3 (469.8 ; 1030.9)
Total breast volume (cm3)a 866.8 (573.9 ; 1256.8) 994.0 (648.6 ;1376.5) 797.5 (531.8 ; 1105.8)
VDG Volpara density grade
aAt first digital screening mammogram
bWomen were followed until breast cancer diagnosis (event), till death or till 2 years after the last available mammogram, whichever came first
Fig. 1 Associations between mammographic measures and breast cancer risk. In the cox proportional hazards analyses age was used as
the underlying time scale. Pt p-trend: this was determined by adding the categorical measures as a continuous measure to the model,
PDV percentage dense volume, DV dense volume, Per SD per standard deviation, VDG Volpara density grade, Q quartile, C category. *Absolute dense
volume (DV) measures were adjusted for nondense (breast fat) volume
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highest compared to the lowest quartiles of DV and
PDV, respectively. The HRs were 1.27 (95% CI 1.14–
1.43) and 1.10 (0.97–1.25) for continuous measures of
DV and PDV, respectively. DV, measured continuously,
had a significantly stronger association with screen-
detected breast cancer risk than continuously measured
PDV (Table 3). Although DV was significantly associated
with screen-detected breast cancer risk, and PDV was
not, the risk estimates for VDG versus VDG-like cat-
egories and PDV versus DV quartiles in relation to
screen-detected breast cancer risk were not statistically
significantly different (Table 3).
Association between breast density measures and
interval breast cancer risk
The association between breast density measures and
interval breast cancer risk is presented in Fig. 2 and
Table 5. All breast density measures were statistically sig-
nificantly associated with increased risks of interval breast
cancer. The HRs were 4.92 (95% CI 2.98–8.12) and 8.37
(95% CI 4.34–16.17) for VDG-like category and VDG
category 4 compared to category 1, respectively and 2.79
(95% CI 1.86–4.19) and 5.89 (95% CI 3.42–10.14) for the
highest compared to the lowest quartiles of DV and PDV,
respectively. Quartiles of PDV were more strongly associ-
ated with interval breast cancer risk than quartiles of DV,
and this difference was statistically significant (Table 3).
The difference in effect between VDG versus VDG-like-
categories was not statistically significantly different. The
continuous measures of PDV and DV were also positively
associated with interval breast cancer risk, with HRs of
1.65 (95% CI 1.45–1.87) and 1.63 (95% CI 1.42–1.87) for
one standard deviation increase in the ln-transformed
continuous measure (not significant (Table 3)).
Table 2 Association between mammographic measures and breast cancer risk
Cases/person years HR1 (95% CI) HR2 (95% CI) HRinvasive (95% CI)
Volpara density grades
VDG1 58/46,089 ref NA ref
VDG2 215/99,086 1.78 (1.33 ; 2.38) NA 1.89 (1.38 ; 2.58)
VDG3 189/73,207 2.38 (1.76 ; 3.20) NA 2.53 (1.83 ; 3.49)
VDG4 61/20,314 3.14 (2.17 ; 4.55) NA 3.54 (2.39 ; 5.24)
P trend <0.001 <0.001
Percent dense volume (in quartiles)
Q1 (<4.8%) 79/58,411 ref NA ref
Q2 (4.8–6.4%) 127/61,153 1.57 (1.19 ; 2.08) NA 1.61 (1.19 ; 2.18)
Q3 (6.4–9.8%) 161/60,499 2.17 (1.65 ; 2.84) NA 2.33 (1.74 ; 3.11)
Q4 (>9.8%) 156/58,633 2.42 (1.83 ; 3.20) NA 2.52 (1.87 ; 3.40)
P trend <0.001 <0.001
Percent dense volume (per SD increase)# 523/238,696 1.36 (1.25 ; 1.48) NA 1.38 (1.26 ; 1.51)
Dense volume (VDG-like categories)
C1 (<39.8 cm3) 69/45,851 ref ref ref
C2 (39.9– 65.2 cm3) 197/96,827 1.37 (1.04 ; 1.80) 1.53 (1.15 ; 2.05) 1.69 (1.24 ; 2.30)
C3 (65.3– 110.1 cm3) 176/74,190 1.66 (1.26 ; 2.20) 2.06 (1.52 ; 2.80) 2.27 (1.63 ; 3.14)
C4 (>110.1 cm3) 81/21,828 2.79 (2.02 ; 3.86) 3.55 (2.49 ; 5.05) 3.66 (2.50 ; 5.36)
P trend <0.001 <0.001 <0.001
Dense volume (in quartiles)
Q1 (<42.9 cm3) 91/57,909 ref ref ref
Q2 (42.9–7.8 cm3) 113/59,364 1.22 (0.93 ; 1.61) 1.35 (1.01 ; 1.80) 1.47 (1.08 ; 1.99)
Q3 (57.9–78.9 cm3) 136/60,359 1.48 (1.13 ; 1.93) 1.77 (1.33 ; 2.35) 1.92 (1.42 ; 2.60)
Q4 (>78.9 cm3) 183/61,065 2.08 (1.61 ; 2.68) 2.60 (1.96 ; 3.45) 2.71 (2.01 ; 3.67)
P trend <0.001 <0.001 <0.001
Dense volume (per SD increase)# 523/238,696 1.34 (1.23 ; 1.46) 1.45 (1.32 ; 1.60) 1.45 (1.32 ; 1.60)
HR1 Cox proportional hazards analysis where age was used as the underlying time scale, HR2 dense volume HR’s are adjusted for nondense volume (quartiles),
HRinvasive Cox proportional hazards analysis with only invasive breast cancers, where age was used as the underlying time scale. Dense volume HRs were adjusted
for nondense volume (quartiles), NA Not applicable
P trend was determined by adding the categorical measures as a continuous measure into the model
#Continuous measures were natural-logarithm-transformed to establish normal distributions
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For all breast measures (except quartiles of DV (p =
0.355)) the risk in relation to interval breast cancer was
statistically significantly stronger than that in relation to
screen-detected breast cancer (Fig. 2). The associations
between percentage dense volume and interval breast
cancer risk seemed somewhat stronger than the associa-
tions between absolute dense volume and interval breast
cancer risk, although this difference between percentage
and absolute dense volume was not consistently statisti-
cally significant (Table 3).
Of the 523 breast cancers in our study, 56 (11%) were
in situ, and 466 (89%) were invasive breast cancers. For
one case of breast cancer, information on invasiveness
was missing. Of the interval cancers, 218 (97%) were in-
vasive breast cancers compared to 83% of screen-
detected cancers. Results restricted to invasive breast
cancers are presented in Tables 2, 4 and 5. In general,
the effects for invasive breast cancer were similar to
those for invasive and in situ cancers combined.
Our results did not change when we only used the
contralateral MLO view for breast cancer cases and the
MLO view of a random chosen side for non-breast can-
cer cases (instead of the mean of the left and right view)
for breast density measurements in relation to breast
cancer risk (data not shown).
For reference and for comparison with other papers,
Additional file 1: Figure S1 and Additional file 2: Figure
S2 are presented with the second instead of the first
breast density categories as the reference category.
Discussion
In this study we found that automatically assessed volu-
metric breast density measures are positively associated
with breast cancer risk and in particular with the risk of
interval cancer. The difference in effect on interval and
screen-detected cancers appeared slightly more pro-
nounced for the percentage dense volume measures than
for absolute dense volume measures. The VDG
Table 3 Percentage dense volume versus dense volume measures in relation to breast cancer risk (bootstrap analysis results)
Total breast cancers Significance of the difference between
coefficients in PDV and DV models
Difference between coefficients
in PDV and DV models
95% CI of difference between
coefficients in PDV and DV models
VDG vs VDG-like categories Non significant C2: 0.15 (-0.25 ; 0.56)
C3: 0.15 (-0.23 ; 0.52)
C4: -0.11 (-0.51 ; 0.27)
Quartiles PDV vs DV Non significant Q2: 0.16 (-0.24 ; 0.54)
Q3: 0.21 (-0.17 ; 0.57)
Q4: -0.07 (-0.37 ; 0.24)
Continuous PDV vs DV Non significant -0.07 (-0.15 ; 0.01)
Screen-detected cancers
VDG vs VDG-like categories Non significant C2: -0.03 (-0.56 ; 0.46)
C3: -0.17 (-0.64 ; 0.28)
C4: -0.49 (-1.08 ; 0.07)
Quartiles PDV vs DV Non significant Q2: -0.14 (-0.65 ; 0.32)
Q3: -0.14 (-0.62 ; 0.34)
Q3: -0.49 (-0.90 ; -0.12)
Continuous PDV vs DV Significant, stronger for DV -0.13 (-0.24 ; -0.03)
Interval cancers
VDG vs VDG-like categories Non significant (except for C2 and C3:
stronger for PDV)
C2: 0.73 (0.01 ; 1.56)
C3: 0.92 (0.26 ; 1.68)
C4: 0.58 (-0.06 ; 1.28)
Quartiles PDV vs DV Significant, stronger for PDV Q2: 0.90 (0.21 ; 1.60)
Q3: 1.02 (0.40 ; 1.66)
Q3: 0.77 (0.26 ; 1.34)
Continuous PDV vs DV non significant 0.01 (-0.11 ; 0.13)
VDG Volpara density grade, PDV percentage dense volume, DV dense volume
Significant: none of the bootstrap 95% CIs for differences between quartile (Q)2, Q3, or Q4 (or category (C)2, C3, or C4) contain zero, otherwise they
were non-significant
Bold text means that the difference between coefficients in PDV an DV models are significant
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categories that are comparable to the BI-RADS categor-
ies had the highest risk estimates for association with
interval breast cancers.
To our knowledge the relationship between volumetric
breast density and risk of screen-detected and interval
cancers, respectively, has not been studied separately be-
fore, but there are several studies on the association be-
tween volumetric breast density, determined on digital
mammograms, and total breast cancer risk. An overview
of their design and results is given in Additional file 3:
Table S1. Four of the five presented studies examined
both absolute and percentage dense volume in relation
to breast cancer risk. In general, the risk estimates for
percentage dense volume are somewhat higher than for
absolute dense volume [15–18]. Although our risk esti-
mates for dense volume and percentage dense volume are
in line with those of the studies presented in Additional
file 3: Table S1, our percentage dense volume risk esti-
mates (VDG, PDV) seem to be slightly lower than in
the other studies [15–18]. This could be explained by
the fact that we do not have information on body mass
index (BMI) or other risk factors in the routine screen-
ing program and therefore could not adjust for these
risk factors. In particular the adjustment for BMI is
known to increase the risk estimates for percent density
measures. Despite this lack of adjustment for BMI, still
the percent dense volume measures in our study appear
to be more strongly related to the risk of interval can-
cer than the absolute dense volume measures.
As mentioned, no other studies have examined the
ability of automated volumetric breast density assess-
ment methods to identify women with a high risk of
interval breast cancer. However, from a breast cancer
screening perspective, this is important to know, since
women with a high risk of interval breast cancer
might benefit most from supplemental screening.
Area-based breast density measures, such as BI-RADS
density and the semi-automatic Cumulus thresholding
method have been studied in relation to interval
cancer risk. In these studies density was found to be
more strongly related to the risk of an interval cancer than
to the risk of a screen-detected cancer [4, 22–26, 29].
Boyd et al. (2014) and Krishnan et al. (2016) were the
only two studies of both absolute dense area and per-
cent dense area in relation to the mode of breast cancer
detection. They too found that breast density was sig-
nificantly more strongly related to the risk of interval
breast cancers than of screen-detected breast cancers.
This difference in effect seemed stronger for percentage
dense area than for absolute dense area, although this
was not formally tested [22, 29].
Likewise, in our study percentage dense volume
seems to be a better marker for interval breast cancer
risk than dense volume. When looking at total breast
cancer risk, this difference between percentage dense
volume and absolute dense volume seems less pro-
nounced. An explanation for this finding could be that
the amount of dense tissue is etiologically relevant for
Fig. 2 Associations between mammographic measures and risk of screen-detected breast cancer (SDC) or interval breast cancer (IC). The Lunn
and McNeil method for competing risk analysis was used. Pt p trend: this was determined by adding the categorical measures as a continuous
measure into the model, PDV percentage dense volume, DV dense volume, Per SD per standard deviation, VDG Volpara density grade, Q quartile,
C VDG-like category. *Absolute dense volume measures were adjusted for nondense (breast fat) volume
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breast cancer risk, and that when this dense tissue is
occupying the larger part of the breast volume, these
women will run a higher risk that a tumor will be
masked at mammography and later diagnosed as inter-
val cancer. If on the other hand, this same amount of
dense tissue is accompanied by a large amount of fat
tissue, large parts of the mammogram may still be well
“readable” for cancer detection, and the probability that
this tumor is detected at the screening examination will
become higher.
Besides masking, another possible explanation for the
relatively larger number of interval breast cancers in
women with dense breasts is tumor aggressiveness. It is
possible that tumors in dense breasts are more aggres-
sive (grow faster) than tumors in nondense breasts.
However, although some studies report that breast dens-
ity is more strongly related to estrogen receptor (ER)-
negative tumors than to ER-positive tumors, this was
not confirmed in other studies [30–34].
When interpreting our results, it should be kept in
mind that we excluded prevalent breast cancer cases
(screen-detected cancers diagnosed as a result of the first
digital screening examination). The proportion of inter-
val cancers is therefore larger (43%) in the current study
than in the Dutch biennial screening program (26%). As
interval cancers are relatively more common in dense
breasts, the association between breast density and total
breast cancer risk is probably somewhat overestimated.
However, this is not the case for analyses separated for
screen-detected and interval breast cancers.
In most European countries women are screened from
the age of 50 years. In the USA most women are
screened from the age of 40 years. In addition, biennial
screening is common in European countries, while in
Table 4 Association between mammographic measures and screen-detected breast cancer risk - Lunn and McNeil
Cases/person years HR1 (95% CI) HR2 (95% CI) HRinvasive (95% CI)
Volpara density grades
VDG1 46/46,089 ref NA ref
VDG2 143/99,086 1.49 (1.07 ; 2.07) NA 1.53 (1.07 ; 2.21)
VDG3 89/73,207 1.43 (0.99 ; 2.05) NA 1.41 (0.94 ; 2.10)
VDG4 21/20,314 1.39 (0.82 ; 2.36) NA 1.41 (0.79 ; 2.54)
P trend 0.147 0.219
Percent dense volume (in quartiles)
Q1 (<4.8%) 63/58,411 ref NA ref
Q2 (4.8–6.4%) 82/61,153 1.27 (0.91 ; 1.76) NA 1.27 (0.89 ; 1.81)
Q3 (6.4–9.8%) 86/60,499 1.47 (1.06 ; 2.04) NA 1.52 (1.06 ; 2.17)
Q4 (>9.8%) 68/58,633 1.36 (0.97 ; 1.94) NA 1.27 (0.86 ; 1.89)
P trend 0.049 0.119
Percent dense volume (per SD increase)# 299/238,696 1.10 (0.97 ; 1.25) NA 1.08 (0.94 ; 1.24)
Dense volume (VDG-like categories)
C1 (<39.8 cm3) 38/45,851 ref ref ref
C2 (39.9–65.2 cm3) 123/96,827 1.55 (1.08 ; 2.23) 1.52 (1.03 ; 2.23) 1.76 (1.14 ; 2.72)
C3 (65.3–110.1 cm3) 101/74,190 1.76 (1.21 ; 2.56) 1.69 (1.11 ; 2.57) 1.99 (1.24 ; 3.17)
C4 (>110.1 cm3) 37/21,828 2.40 (1.52 ; 3.79) 2.30 (1.39 ; 3.80) 2.03 (1.13 ; 3.67)
P trend <0.001 0.002 0.014
Dense volume (in quartiles)*
Q1 (<42.9 cm3) 48/57,909 ref ref ref
Q2 (42.9–57.8 cm3) 71/59,364 1.46 (1.01 ; 2.10) 1.45 (0.99 ; 2.13) 1.62 (1.06 ; 2.48)
Q3 (57.9–78.9 cm3) 80/60,359 1.67 (1.16 ; 2.39) 1.67 (1.13 ; 2.47) 1.86 (1.21 ; 2.87)
Q4 (>78.9 cm3) 100/61,065 2.22 (1.57 ; 3.14) 2.24 (1.51 ; 3.31) 2.31 (1.49 ; 3.58)
P trend <0.001 <0.001 <0.001
Dense volume (per SD increase)# 299/238,696 1.27 (1.14 ; 1.43) 1.27 (1.11 ; 1.45) 1.22 (1.05 ; 1.41)
HR1 Lunn and McNeil method was used for competing risk analysis, HR2 dense volume HR’s were additionally adjusted for nondense volume (quartiles), HRinvasive
Cox proportional hazards analysis with only invasive breast cancers, where age was used as the underlying time scale. Dense volume HRs were adjusted for
nondense volume (quartiles). P trend was determined by adding the categorical measures as a continuous measure into the model, NA Not applicable
#Continuous measures were natural-logarithm-transformed to establish normal distributions
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the USA many women are screened yearly. We therefore
looked at interval cancers diagnosed within the first year
after a screening mammogram. We observed that 22%
of the interval cancers in the group with the lowest
breast density was found in that first year, while this was
60% in the group with the highest breast density, indi-
cating an even stronger association between breast dens-
ity and risk of interval breast cancer within the first year
after screening.
A limitation of our study is that we could not compare
the association between the automated volumetric dens-
ity measurements and breast cancer risk with those of
other commonly used breast density measurements such
as BI-RADS. The reason for this is that BI-RADS density
readings are not routinely performed in the Dutch breast
cancer screening program. Previous studies directly
comparing automated density measuring methods to BI-
RADS density readings and other breast density mea-
surements in relation to breast cancer risk identified
similar positive associations for all density measure-
ments, although they may differ in their classification of
which women have dense breasts and which women
have not [15–18, 35, 36]. It remains as yet unknown
which method most accurately reflects true density [17].
The method that we used in our study has been vali-
dated against MRI measurements of the fibroglandular
tissue volume and by its fully automatic nature this gives
objective and reproducible density measurements [13].
Although BI-RADS density is known to be strongly asso-
ciated with breast cancer and interval breast cancer risk,
the inter-reader reproducibility using this method is
moderate [8–12]. A critical issue now in the discussion
of the value of supplemental imaging for women with
dense breasts is that it may depend on the radiologist
Table 5 Association between mammographic measures and interval breast cancer risk - Lunn and McNeil
Cases/person years HR1 (95% CI) HR2 (95% CI) HRinvasive (95% CI)
Volpara density grades
VDG1 12/46,089 ref NA ref
VDG2 72/99,086 2.85 (1.55 ; 5.25) NA 3.03 (1.61 ; 5.73)
VDG3 100/73,207 5.61 (3.07 ; 10.27) NA 6.01 (3.20 ; 11.27)
VDG4 40/20,314 8.37 (4.34 ; 16.17) NA 9.30 (4.71 ; 18.37
P trend <0.001 <0.001
Percent dense volume (in quartiles)
Q1 (<4.8%) 16/58,411 ref NA ref
Q2 (4.8–6.4%) 45/61,153 2.72 (1.54 ; 4.82) NA 2.78 (1.55 ; 5.01)
Q3 (6.4–9.8%) 75/60,499 4.71 (2.74 ; 8.10) NA 4.99 (2.86 ; 8.72)
Q4 (>9.8%) 88/58,633 5.89 (3.42 ; 10.14) NA 6.22 (3.56 ; 10.89)
P trend <0.001 <0.001
Percent dense volume (per SD increase)# 224/238,696 1.65 (1.45 ; 1.87) NA 1.68 (1.48 ; 1.91
Dense volume (VDG-like categories)
C1 (<39.8 cm3) 31/45,851 ref ref ref
C2 (39.9–65.2 cm3) 74/96,827 1.13 (0.75 ; 1.73) 1.43 (0.92 ; 2.21) 1.48 (0.95 ; 2.30)
C3 (65.3–110.1 cm3) 75/74,190 1.51 (0.99 ; 2.29) 2.32 (1.48 ; 3.64) 2.32 (1.47 ; 3.67)
C4 (>110.1 cm3) 44/21,828 3.01 (1.89 ; 4.79) 4.92 (2.98 ; 8.12) 5.24 (3.16 ; 8.70)
P trend <0.001 <0.001 <0.001
Dense volume (in quartiles)*
Q1 (<42.9 cm3) 43/57,909 ref ref ref
Q2 (42.9–57.8 cm3) 42/59,364 0.95 (0.62 ; 1.46) 1.14 (0.74 ; 1.77) 1.22 (0.78 ; 1.90)
Q3 (57.9–78.9 cm3) 56/60,359 1.25 (0.84 ; 1.87) 1.74 (1.14 ; 2.66) 1.83 (1.19 ; 2.81)
Q4 (>78.9 cm3) 83/61,065 1.83 (1.26 ; 2.66) 2.79 (1.86 ; 4.19) 2.89 (1.91 ; 4.38)
P trend <0.001 <0.001 <0.001
Dense volume (per SD increase)# 224/238,696 1.39 (1.22 ; 1.59) 1.63 (1.42 ; 1.87) 1.65 (1.44 ; 1.90)
HR1 Lunn and McNeil method was used for competing risk analysis, HR2 dense volume HRs were adjusted for nondense volume (quartiles), HRinvasive Cox
proportional hazards analysis with only invasive breast cancers, where age was used as the underlying time scale. Dense volume HRs were adjusted for nondense
volume (quartiles). P trend was determined by adding the categorical measures as a continuous measure into the model, NA Not applicable
#Continuous measures were natural-logarithm-transformed to establish normal distributions
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who interprets the mammograms as to whether a
woman is classified as having dense breasts or not [12].
Another limitation is that at the time the mammo-
graphic examinations were performed, the CC view was
not a routine view in our screening program. The CC
view was only taken when women had their first screen-
ing examination, or on indication, e.g. because of high
breast density or suspect lesions. Although for robust-
ness of volumetric breast density estimates it may have
been preferable to calculate density on MLO and CC
views, in our study we did this on the MLO view only,
to prevent effect estimates from being biased by the se-
lective availability of the CC views.
A final limitation is that we only had information
about age as an important confounder. Therefore, ad-
justment of the risk estimates for other confounders was
not possible. The inability to adjust for parity and other
reproductive factors may have overestimated the risk es-
timates somewhat both for dense volume and percent
dense volume. Not adjusting for BMI is expected to have
led to an underestimation of the risk estimate of per-
centage dense volume in particular, but all in all, the risk
estimates for total breast cancer risk are quite compar-
able to what has been published in other papers on volu-
metric breast density [15–18, 37]. Besides that, our study
could be seen as an example for other screening pro-
grams where often little or no information is available
on risk factors other than age.
Strengths of our study are the large cohort, the availabil-
ity of unprocessed digital data for all its participants and
its follow up since 2003 when digital mammography
screening was introduced in the Netherlands. Due to link-
age with the Netherlands Cancer Registry, which covers
all residents of the Netherlands and is more than 95%
complete, we have virtually complete information not only
on screen-detected, but also on interval breast cancers.
Conclusion
We found that automated breast density measures can
be used for breast cancer risk assessment and in particu-
lar, for the risk of a tumor that is not detected at the
breast cancer screening. Automated measures are espe-
cially useful in programs where BI-RADS is not rou-
tinely determined or to improve reproducibility.
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